title: Side effects and good effects from new chemotherapeutic agents. Case 3. Bortezomib in primary refractory plasmacytoma.
authors.affiliation: University Departments of Medicine, Radiology and Pathology, Queen Mary Hospital, University of Hong Kong, Hong Kong.
authors.forename: C S
authors.initials: CS
authors.lastname: Chim
authors.forename: G C
authors.initials: GC
authors.lastname: Ooi
authors.forename: F
authors.initials: F
authors.lastname: Loong
authors.forename: A W M
authors.initials: AW
authors.lastname: Au
authors.forename: A K W
authors.initials: AK
authors.lastname: Lie
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008479:Mediastinal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D010954:Plasmacytoma / Q000188:drug therapy* / Q000473:pathology; D011719:Pyrazines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib